

Juan Alberola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6183363/publications.pdf>

Version: 2024-02-01

28
papers

310
citations

1040056

9
h-index

940533

16
g-index

30
all docs

30
docs citations

30
times ranked

381
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine. <i>Journal of Infection</i> , 2022, 84, 418-467.	3.3	3
2	Comparison of quick Pitt to quick sofa and sofa scores for scoring of severity for patients with urinary tract infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 1321-1326.	2.0	2
3	Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, 8273.	3.3	5
4	Prognostic accuracy of Quick SOFA in older adults hospitalised with community acquired urinary tract infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e14620.	1.7	3
5	Clinical impact of multidrug-resistant bacteria in older hospitalized patients with community-acquired urinary tract infection. <i>BMC Infectious Diseases</i> , 2021, 21, 1232.	2.9	11
6	Predictive factors for <i>Enterococcus faecalis</i> in complicated community-acquired urinary tract infections in older patients. <i>Geriatrics and Gerontology International</i> , 2020, 20, 183-186.	1.5	5
7	COVID-19 and post-mortem microbiological studies. <i>Spanish Journal of Legal Medicine</i> , 2020, 46, 127-138.	0.2	10
8	COVID-19 y estudios microbiológicos post mortem. <i>Revista Espanola De Medicina Legal</i> , 2020, 46, 127-138.	0.1	5
9	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
10	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
11	Community-onset <i>Pseudomonas aeruginosa</i> urinary sepsis in elderly people: Predictive factors, adequacy of empirical therapy and outcomes. <i>International Journal of Clinical Practice</i> , 2019, 73, e13425.	1.7	3
12	Missing Cases of Herpes Simplex Virus (HSV) Infection of the Central Nervous System When the Reller Criteria Are Applied for HSV PCR Testing: a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	7
13	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2331-2339.	2.9	7
14	Prospective cohort study of risk factors for extended-spectrum β -lactamase-producing <i>Escherichia coli</i> urinary tract infections in elderly patients admitted to hospital. <i>International Journal of Clinical Practice</i> , 2017, 71, e13001.	1.7	15
15	Assessing the risk of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma. <i>Journal of General Virology</i> , 2017, 98, 1855-1863.	2.9	2
16	Effect of Bacteremia in Elderly Patients With Urinary Tract Infection. <i>American Journal of the Medical Sciences</i> , 2016, 352, 267-271.	1.1	27
17	Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting. <i>Clinical Transplantation</i> , 2014, 28, 508-511.	1.6	0
18	Influence of inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract infections. <i>European Journal of Internal Medicine</i> , 2014, 25, 523-527.	2.2	46

#	ARTICLE	IF	CITATIONS
19	Need to evaluate the performance of real-time PCR assays for the quantitation of cytomegalovirus DNA load in lower respiratory tract specimens. <i>Critical Care</i> , 2013, 17, 465.	5.8	0
20	Becton Dickinson Directigen EZ Flu A+B assay in the diagnosis of pandemic influenza A H1N1 2009 virus infection in adult patients. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 146-147.	3.4	3
21	Enumeration of cytomegalovirus-specific interferon γ CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. <i>Haematologica</i> , 2008, 93, 1434-1436.	3.5	49
22	Assessment of human cytomegalovirus specific T cell immunity in human immunodeficiency virus infected patients in different disease stages following HAART and in long-term non-progressors. <i>Journal of Medical Virology</i> , 2004, 74, 382-389.	5.0	4
23	Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART. <i>Journal of Clinical Virology</i> , 2004, 29, 308-314.	3.1	2
24	Application of a 5-bromo-2 α -deoxyuridine ELISA for measuring the lymphoproliferative response to human cytomegalovirus in HIV-1-infected patients. <i>Journal of Virological Methods</i> , 2002, 105, 247-251.	2.1	6
25	Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. <i>Journal of Medical Virology</i> , 2001, 64, 35-41.	5.0	17
26	Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. <i>Journal of Medical Virology</i> , 2001, 65, 77-84.	5.0	16
27	Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct clinical presentations of primary HCMV infection. <i>Journal of Clinical Virology</i> , 2000, 16, 113-122.	3.1	17
28	Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease. , 1998, 55, 272-280.		13